Search Site:

Main menu:


DFCI HMS Broad

Home

The Novina Lab has been driven by two fundamental questions: (1) what is the mechanism by which microRNAs affect gene expression and (2) how does dysregulation of microRNA pathways influence oncogenesis? We use classical biochemistry, combinatorial biochemistry, systematic genomics, computational approaches and advanced technologies to develop a deeper understanding of the biology of RNAs and their altered functions in disease. Additionally, altered microRNA expression has been used to classify diseases and many microRNA genes exhibit aberrant promoter hypo- and hyper-methylation in cancers. To study the causes and consequences of inappropriate DNA methylation of microRNA and other disease-relevant genes, we are developing “epigenetic engineering” tools that will enable site-specific addition and removal of methyl groups on DNA. By understanding biological processes at the most fundamental levels, we are gaining greater insights into disease processes and developing the tools to treat these diseases.

Postdoctoral position is available to lead a project focused on the biology and mechanisms of disease-relevant long non-coding RNAs (lncRNAs). The ideal candidate will have experience with RNA and protein biochemistry and molecular biology, and a desire to develop the translational potential of lncRNAs. He or she will integrate computational analyses, systems approaches, and advanced biochemical technologies to understand lncRNA biology ex vivo and in vivo. This position will work closely with other researchers and clinicians towards these goals. Interested candidates should contact Carl Novina (carl_novina@dfci.harvard.edu) for details.

Links related to Novina Lab research
DFCI Researcher Profile
CIA Faculty Profile
DF/HCC Member Profile
BBS Rotation Manual Profile
Immunology Rotation Manual Profile
Office of Research and Technology Ventures
Dr. Novina’s Youtube video on epigenetic reprogramming
Dr. Novina wins the 2015 NIH Directors’ Pioneer Award
Dr. Novina’s Interviews with International Innovation in 2013 and 2014

siRNA